Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

rem systems pty ltd - 47760 - intravascular/intracavitary-circulation hyperthermia system - the performer ht (hyperthermic therapies) is intended for use up to 6 hours in the extracorporeal circulation of fluids during hyperthermic perfusion procedures, when used by a qualified medical professional who is experienced in the operation of this or similar equipment.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - axicabtagene ciloleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: albumin; sodium chloride; dimethyl sulfoxide - cellular therapies - yescarta is a genetically modified autologous immunocellular therapy for the treatment of relapsed or refractory large b-cell lymphoma after two or more lines of systemic therapy, including diffuse large b-cell lymphoma (dlbcl) not otherwise specified, primary mediastinal large b-cell lymphoma, high grade b-cell lymphoma, and dlbcl arising from follicular lymphoma. yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - axicabtagene ciloleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: dimethyl sulfoxide; sodium chloride; albumin - cellular therapies - yescarta is a genetically modified autologous immunocellular therapy for the treatment of:large b-cell lymphoma - patients with relapsed or refractory large b-cell lymphoma (lbcl).yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. follicular lymphoma - patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

endotherapeutics pty ltd - 37231 - catheter, hyperthermia unit, uterine ablation - a dedicated balloon catheter used together with a hyperthermia unit, which has a heating element at the distal end. after it is introduced into the uterus, the balloon is filled with water and pressed against the uterus wall.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

solta medical australia pty ltd - 40777 - transducer assembly, ultrasound, therapeutic, hyperthermia, extracorporeal - an ultrasound (us) transducer assembly which is a component of an ultrasound-based hyperthermia system that is used to induce systemic or local heating of sufficient magnitude to create a targeted therapeutic effect on adipose tissue.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

merz australia pty ltd - 40777 - transducer assembly, ultrasound, therapeutic, hyperthermia, extracorporeal - a transducer assembly component of the ulthera ultrasound system that is used to induce systemic or local heating to create a targeted therapeutic effect. it is mounted within the handpiece of the hyperthermia system and allows the operator to position the transducer assembly external to the patient during treatments. it is composed of an array of transducer elements and associated damping, backing, and matching layer materials.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 100 mg/ml; riboflavine sodium phosphate, quantity: 2 mg/ml; nicotinamide, quantity: 20 mg/ml; dexpanthenol, quantity: 20 mg/ml; pyridoxine hydrochloride, quantity: 40 mg/ml; cyanocobalamin, quantity: 0.4 mg/ml - injection, solution - excipient ingredients: disodium edetate; benzyl alcohol; water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. 5. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. 6. peripheral neuritis caused by various b group deficiencies. 7. carpal tunnel syndrome. 8. pernicious anaemia as a result of in situ b12 deficiency. general indications include: 1. angular stomatitis and glossitis have been shown in some instances to respond to t

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - riboflavine sodium phosphate, quantity: 5 mg/ml; nicotinamide, quantity: 50 mg/ml; dexpanthenol, quantity: 25 mg/ml; pyridoxine hydrochloride, quantity: 50 mg/ml; cyanocobalamin, quantity: 250 microgram/ml - injection, solution - excipient ingredients: disodium edetate; water for injections; benzyl alcohol - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. commonly, several b vitamin deficiencies may occur similtaneously. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. note: b-dose plus 2ml injection does not contain thiamine. 5. peripheral neuritis caused by various b group de

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 50 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; pyridoxine hydrochloride, quantity: 5 mg/ml; dexpanthenol, quantity: 2.5 mg/ml; nicotinamide, quantity: 25 mg/ml; cyanocobalamin, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. 5. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. 6. peripheral neuritis caused by various b group deficiencies. 7. pernicious anaemia as a result of in

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - riboflavine sodium phosphate, quantity: 5 mg/ml; nicotinamide, quantity: 50 mg/ml; dexpanthenol, quantity: 25 mg/ml; pyridoxine hydrochloride, quantity: 50 mg/ml; cyanocobalamin, quantity: 250 microgram/ml - injection, solution - excipient ingredients: disodium edetate; water for injections; benzyl alcohol - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. commonly, several b vitamin deficiencies may occur similtaneously. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. note: b-dose plus 2ml injection does not contain thiamine. 5. peripheral neuritis caused by various b group de